Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors

Trial Profile

A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs CS 1001 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors CStone Pharmaceuticals
  • Most Recent Events

    • 04 Jun 2018 According to a Blueprint Medicines and CStone Pharmaceuticals media release, phase Ia (dose escalation) portion was completed in May 2018, and the phase Ib (dose expansion) portion has recently started patient recruitment.
    • 19 Jul 2017 New trial record
    • 17 Jul 2017 According to a CStone Pharmaceuticals media release, the company received Clinical Trial Application (CTA) approval from the China Food and Drug Administration (CFDA) to conduct clinical trials in China with the investigational agent CS1001.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top